Imovac SA
Imovac reported total assets of €4.45m at the end of the 2025 financial year (annual accounts filed with the NBB on 14 Jul 2026).
The score of Imovac shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +104 % Total assets +44 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Imovac's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Jul 2026
- Year ended 31 Dec 2024filed on 25 Jul 2025
- Year ended 31 Dec 2023filed on 07 Jun 2024
- Year ended 31 Dec 2022filed on 22 Jun 2023
- Year ended 31 Dec 2021filed on 21 Mar 2022
Imovac's financial analysis
- Solvency80.5%sector median: 18.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Imovac
Imovac's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0436.578.588
- VAT number
- BE0436578588
- Peppol
- Registered · 0208:0436578588 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 17 Jan 1989
- Registered office
- 1040 Etterbeek
- Latest accounts
- 2025 · filed on 14 Jul 2026
- Activity
- Buying and selling of own real estate (NACE 68110)
Imovac (SA) has been based in Etterbeek since 1989, active in: buying and selling of own real estate. For 2025, it reports a net profit of 45,394 € and equity of €3.59m; its revenue is not published. Its solvency stands at 80.5%, above the median of its sector (18.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Imovac
Companies in the same business, of comparable size and area, outside its group.
- Retail Partners Buying and selling of own real estate Uccle · balance sheet €2.17m
- Vauban Buying and selling of own real estate Brussels · balance sheet €10.5m
- KS Company Buying and selling of own real estate Ixelles · balance sheet €1.78m
- Vertige Intermediation service activities for real estate activities Uccle · balance sheet 243,924 €
- Rosae Intermediation service activities for real estate activities Brussels · balance sheet €1.72m
- Vleurgat Center House Buying and selling of own real estate Watermael-Boitsfort · balance sheet €7.03m
- LGV Buying and selling of own real estate Herent · balance sheet €6.22m
- VAS Buying and selling of own real estate Ghent · balance sheet €9.33m
Frequently asked questions about Imovac
What is the revenue of Imovac?
Imovac files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Imovac?
In Belgium, the VAT number is the company number prefixed with BE: BE0436578588 for Imovac, if the company is VAT-registered. Its company number (CBE) is 0436.578.588.
Where is the registered office of Imovac?
According to the CBE register, the registered office of Imovac is in 1040 Etterbeek.
What is the equity of Imovac?
At the close of the 2025 financial year, the equity of Imovac amounts to 3,586,560 €, a solvency of 80.5% of total assets.
Who manages Imovac?
The register lists 6 active mandates at Imovac. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Imovac
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →